Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
Open Access
- 15 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (Supplement) , S282-S292
Abstract
Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods: A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab’s impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results: Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions: An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.Keywords
Funding Information
- AstraZeneca
- Sanofi
This publication has 38 references indexed in Scilit:
- Respiratory syncytial virus immunization program for the United States: Impact of performance determinants of a theoretical vaccineVaccine, 2013
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePediatrics, 2013
- Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenCochrane Database of Systematic Reviews, 2013
- Prospective Multicenter Study of Viral Etiology and Hospital Length of Stay in Children With Severe BronchiolitisArchives of Pediatrics & Adolescent Medicine, 2012
- Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997–2006The Pediatric Infectious Disease Journal, 2012
- Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infantsJournal of Medical Economics, 2011
- Epidemiology and etiology of childhood pneumoniaBulletin of the World Health Organization, 2008
- Palivizumab prophylaxis in haemodynamically significant congenital heart disease * Authors' replyArchives of Disease in Childhood, 2005
- Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infectionArchives of Disease in Childhood, 2001
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998